I think maybe the money's what's throwing you off here today.
Followers | 199 |
Posts | 17,208 |
Boards Moderated | 2 |
Alias Born | 02/17/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Holding
OCGN
OCGN might be finally heating up
Holding
OCGN
Holding
OCGN
Holding
OCGN
HOLDING
OCGN
OCGN
Holding
OCGN
Exactly.
Holding.
OCGN
Holding
OCGN
OCGN 7.15
OCGN 7.15
Vanguard increased their position by ~1.8M shares to 10.8M, up from ~9M. $OCGN #COVAXIN https://t.co/rtYOjRpIUT
— Billythekid123 (@B1llyTh2K3d) November 12, 2021
That puts their institutional ownership at ~6% pic.twitter.com/geHC9Y7zj7
He’s doing great imo
OCGN
HOLDING
OCGN
OCGN holding
OCGN 5min chart wants the breakout.
Underground gem.
$OCGN // EZDD LINKS
ir.ocugen.com/static-files/0598035e-1c55-4943-aa93-e71c0548a92a
ir.ocugen.com/news-releases/
ir.ocugen.com/financial-information/sec-filings
ocugen.com/pipeline/ocu200/
ocugen.com/pipeline/ocu400/
clinicaltrials.gov
www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html
pubmed.ncbi.nlm.nih.gov/?term=Bbv152
www.nih.gov/news-events/news-releases/adjuvant-developed-nih-funding-enhances-efficacy-indias-covid-19-vaccine
OCGN
Are you in?
OCGN
Today’s 8K is pretty decent. And Cramer is a “seller”. 69m shares on loan.
So who’s been following along here?
OCGN
Bottom.
OCGN
Get ready.
OCGN
Correct. Hold.
OCGN
Holding from .003
GLCO
OCGN “Ocugen initiated with an Outperform at Noble Capital”
Noble Capital analyst Robert LeBoyer initiated coverage of Ocugen with an Outperform rating and $15 price target. The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that has advantages over the the current vaccines in use today, LeBoyer tells investors in a research note.
https://m.thefly.com/news-story/3341723/2021-07-26%2010:00:13/search
OCGN “Ocugen initiated with an Outperform at Noble Capital”
Noble Capital analyst Robert LeBoyer initiated coverage of Ocugen with an Outperform rating and $15 price target. The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that has advantages over the the current vaccines in use today, LeBoyer tells investors in a research note.
https://m.thefly.com/news-story/3341723/2021-07-26%2010:00:13/search
OCGN “Ocugen initiated with an Outperform at Noble Capital”
Noble Capital analyst Robert LeBoyer initiated coverage of Ocugen with an Outperform rating and $15 price target. The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that has advantages over the the current vaccines in use today, LeBoyer tells investors in a research note.
https://m.thefly.com/news-story/3341723/2021-07-26%2010:00:13/search